January 18, 2023 Lupin Launches Sacubitril and Valsartan Combination Drug for Heart Failure Patients

Mumbai, India, January 18, 2023: Global pharma major Lupin Limited (Lupin) today announced the launch of combination drug Sacubitril and Valsartan under two brand names, Valentas and Arnipin, in India. This drug combination is indicated for patients with Heart Failure (HF) conditions. Valentas and Arnipin tablets are available in 200 mg, 100 mg, and 50 mg.

In India, HF remains one of the most prevalent causes of death in patients suffering from chronic heart failure and the estimated prevalence ranges from 1.3 to 4.6 million¹. In addition, the HF pattern in India is considered different from the rest of the world² due to factors such as the average age of Indian patients with HF being 10 years younger than the global average, the high prevalence of hypertension and diabetes, and limited adoption of guideline-directed medical therapy, among others. Valentas and Arnipin are indicated to reduce repeated hospitalization and the risk of cardiovascular death among adult patients with chronic mild to moderate heart failure.

Commenting on the launch, Rajeev Sibal, President - India Region Formulations, Lupin said, "Heart failure is a difficult condition with severe unmet needs, necessitating the development of treatment agents to improve patient outcomes. As a leader in the cardiac therapy area, Lupin is committed to offer patients with treatment options that limit the need for hospitalization and reduce the risk of death. The launch of Valentas and Arnipin aligns with this commitment and offers patients an important treatment option and fulfils an unmet need, while reducing the cost of therapy."

About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.

The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women's health areas. Lupin is the third largest pharmaceutical company in the U.S. by prescriptions. The company invested 8.7% of its revenue on research and development in FY22.

Lupin has 15 manufacturing sites, 7 research centres, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

Please visit www.lupin.com for more information.
Follow us on Twitter: https://twitter.com/LupinGlobal
LinkedIn: https://www.linkedin.com/company/lupin
Facebook: http://www.facebook.com/LupinWorld/

For further information or queries please contact -

Shweta Munjal
Vice President & Global Head - Corporate Communications
Email: [email protected]

References

1: Savarese G, Becher PM, Lund LH, Seferovic P, Rosano G, Coats AJ. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovascular Research. 2022 Feb 12.

2: Chopra VK, Harikrishnan S, Bhattacharya D. Heart Failure in Different Asian Populations. InHypertension and Cardiovascular Disease in Asia 2022 (pp. 171-181). Springer, Cham